✦ LIBER ✦

PUK8 A REVIEW: DIFFERING COSTS AND EFFECTS IN ECONOMIC EVALUATIONS OF TOLTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER

✍ Scribed by SJ Snedecor; MF Botteman; D Weinstein; J Trocio

Book ID: 118609647
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 74 KB
Volume: 11
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)70953-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PUK12 COST-EFFECTIVENESS OF TOLTERODINE

PUK12 COST-EFFECTIVENESS OF TOLTERODINE AS TREATMENT FOR OVERACTIVE BLADDER (OAB) IN ADULT MEXICAN PATIENTS

✍ H. Arreola-Ornelas; A. Rosado-Buzzo; M. Garcia-Mollinedo; L. Camacho-Cordero; E. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

PUK8 FESOTERODINE IS COST-EFFECTIVE FOR

PUK8 FESOTERODINE IS COST-EFFECTIVE FOR THE TREATMENT OF OVERACTIVE BLADDER: RESULTS OF AN ECONOMIC MODEL

✍ C Kelleher; SJ Snedecor; MF Botteman; R Lee; H Najib; D Weinstein; JN Trocio 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

PUK11 UPDATED ECONOMIC ANALYSIS OF FESOT

PUK11 UPDATED ECONOMIC ANALYSIS OF FESOTERODINE RELATIVE TO TOLTERODINE AND SOLIFENACIN FOR THE TREATMENT OF OVERACTIVE BLADDER: THE SWEDISH PERSPECTIVE

✍ R. Lee; S.J. Snedecor; M.G. Kvasz; J. Trocio; B. Borgman 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

PUK6 FESOTERODINE FOR THE TREATMENT OF O

PUK6 FESOTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER—A COST-EFFECTIVENESS CASE STUDY OF SWEDEN

✍ C Prütz; S Snedecor; M Botteman; J Trocio; D Weinstein 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

PUK14 Cost-Effectiveness Analysis of Mir

PUK14 Cost-Effectiveness Analysis of Mirabegron Versus Tolterodine Extended Release in the Treatment of Patients With Overactive Bladder in the United States

✍ J. Xie; Z.Y. Zhou; C.N. Bui; Y. Yan; G. De; M.C. Runken; E.Q. Wu 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

Cost-effectiveness of new treatments for

Cost-effectiveness of new treatments for overactive bladder: The example of tolterodine, a new muscarinic agent: A Markov model

✍ Gisela Kobelt; Linus Jönsson; Anders Mattiasson 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

Economic analyses of interventions for chronic diseases require evaluations over a long timeframe to illustrate the benefits and costs of treatments. Clinical trials are generally short and carried out in strictly controlled conditions. They are therefore of limited value for economic evaluation aim